Roth Capital Weighs in on Cyclacel Pharmaceuticals, Inc.’s FY2028 Earnings (NASDAQ:CYCC)

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) – Equities research analysts at Roth Capital issued their FY2028 earnings per share (EPS) estimates for Cyclacel Pharmaceuticals in a research report issued to clients and investors on Thursday, May 2nd. Roth Capital analyst J. Aschoff forecasts that the biotechnology company will post earnings per share of $16.10 for the year. The consensus estimate for Cyclacel Pharmaceuticals’ current full-year earnings is ($18.70) per share.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($6.35) by $0.12. The company had revenue of $0.03 million for the quarter.

Several other brokerages have also weighed in on CYCC. StockNews.com initiated coverage on Cyclacel Pharmaceuticals in a report on Thursday, May 2nd. They issued a “hold” rating for the company. Roth Mkm reduced their price target on shares of Cyclacel Pharmaceuticals from $21.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, May 3rd.

Cyclacel Pharmaceuticals Stock Performance

CYCC opened at $2.11 on Monday. The company has a market capitalization of $2.79 million, a P/E ratio of -0.08 and a beta of 0.54. The company has a 50-day moving average of $2.16 and a 200-day moving average of $3.41. Cyclacel Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $13.20.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.